Pathophysiology of chronic rhinosinusitis, pharmaceutical therapy options

GMS Curr Top Otorhinolaryngol Head Neck Surg. 2015 Dec 22:14:Doc09. doi: 10.3205/cto000124. eCollection 2015.

Abstract

Research in immunology has brought great progress in knowledge of inflammatory processes in the last 2 decades, which also has an impact on the upper airways. Our understanding of the pathophysiology of chronic rhinosinusitis developed from a rather mechanistic point of view with a focus on narrow clefts and mucociliary clearance to the appreciation of a complex network of immunological pathways forming the basis of disease. We today differentiate various forms of inflammation, we start to understand complex immune-regulatory networks and the reasons for their failure, and have already developed innovative approaches for therapy for the most severely ill subjects. Due to this new knowledge in inflammation and remodeling processes within mucosal tissue, specifically on the key driving factors, new diagnostic tools and therapeutic approaches for chronic rhinosinusitis have developed; the differentiation of endotypes based on pathophysiological principles will be crucial for the use of innovative therapies, mostly humanized monoclonal antibodies. Several hundred of those antibodies are currently developed for various indications and will impact our specialty as well as pneumology to a great extent.

Keywords: Staphylococcus aureus; biologics; chronic rhinosinusitis; cluster analysis; endotypes; pathophysiology; phenotypes.

Publication types

  • Review